<DOC>
	<DOC>NCT00683436</DOC>
	<brief_summary>This will be a multi-center, randomized, blinded, comparative, placebo-controlled, 4 arm crossover study in patients with primary insomnia.</brief_summary>
	<brief_title>Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs</brief_title>
	<detailed_description>Prospective patients will spend 2 nights in the sleep lab for baseline PSG assessments. Those who meet the protocol inclusion/exclusion criteria will return for four treatment periods with two consecutive nights in each. Study medication will be administered in the sleep laboratory 30 minutes before the patient's usual bedtime.</detailed_description>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Adipiplon</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Be between the ages of 21 and 64 years, inclusive; Have a body mass index (BMI) between 21 and 34 kg/m2, inclusive; Be a primary insomniac as defined by DSMIV criteria; in particular difficulty with both sleep initiation and sleep maintenance; Have subjective Latency to Sleep Onset &gt; 45 minutes; Have a mean habitual subjective TST of &lt;6.5 hours; Have a TST of 240 420 minutes at each of two baseline PSGs; Have a mean LPS &gt; 20min, with neither value &lt;15 minutes and mean WASO &gt; 40 minutes on baseline PSGs; Be in good general health as determined by a thorough medical history and physical examination (including vital signs), 12lead ECG and clinical laboratory tests; Have clinical laboratory values within normal reference range or not clinically significantly abnormal as judged by the Principal Investigator; Be off any investigational drug for at least 30 days prior to screening; If the patient is a female of childbearing potential, she must be using an acceptable method of contraception, must have a negative serum pregnancy test at screening, and must have a negative urine pregnancy test before randomization. Female patients who have been surgically sterilized or have had a hysterectomy are eligible if they have a negative pregnancy test at screening; Be able to read, understand, and provide written/dated informed consent before enrolling in the study, and must be willing to comply with all study procedures. Clinically significant unstable medical illness; Evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease; History of cancer other than basal cell carcinoma, squamous cell carcinoma of the skin or cancer in situ within 5 years of screening; Supine or sitting blood pressure &gt; 140/90 mmHg at the screening or baseline visits; Heart rate &gt;100 bpm at the screening or baseline visits; Within the past three years, clinically significant psychiatric illness, including chronic psychiatric illness or any Axis I condition; History or presence of chronic pain; History of epilepsy or serious head injury; Other than primary insomnia, a history of clinically significant sleep disorder including narcolepsy, parasomnia as an adult, circadian rhythm disorder, restless leg syndrome, or on the initial baseline PSG, sleep apnea [Apnea Hypopnea Index (AHI) &gt;10] or Periodic Limb Movement Disorder [Periodic Limb Movement Arousal Index (PLMAI) &gt; 10]; Any condition that may affect drug absorption; Smokers who habitually smoke more than 10 cigarettes per day or smoke during the overnight hours; Travel across more than three time zones, an expected change in sleep schedules of 3 hours or more, or involvement in rotating shift work within 14 days prior to screening or during the study period; Selfreport of napping ≥30 minutes more than 2 times per week within the last month; Any clinically significant abnormal finding on physical examination, vital signs, ECG, or clinical laboratory tests, as determined by the investigator. (The QTc interval must be ≤430 msec. for males and ≤450 msec for females); Known or suspected diagnosis of Acquired Immune Deficiency Syndrome, or previous or current positive result on human immunodeficiency virus antibody or antigen testing; History or laboratory finding of positive hepatitis B surface antigen or hepatitis C core antibody; History of allergies, or known sensitivity, hypersensitivity, or adverse reaction to any drug similar to adipiplon, including benzodiazepines, or zolpidem, zaleplon, zopiclone, or eszopiclone; Use of any psychotropic medications, including overthecounter (OTC) and herbal products, that may affect sleep/wake function within one week or five halflives (whichever is longer) prior to screening or need to use any of these medications at any time during the study; Pregnant or lactating females; Positive serum pregnancy test at screening or urine pregnancy test at baseline; Recent history (≤ one year) of alcohol or drug abuse, or current evidence of substance dependence or abuse as defined by DSMIV criteria; Regular consumption of large amounts of xanthinecontaining substances (i.e. more than 5 cups of coffee or equivalent amounts of xanthinecontaining substances per day); Have eaten grapefruit or had grapefruit juice from baseline through the completion of study dosing; Self report of a usual consumption of more than 14 units of alcohol per week; Requiring the concomitant usage of any 3A4 inhibitors; Any prior exposure to adipiplon (formerly known as NG273).</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>insomnia</keyword>
</DOC>